Transfusion independence and cytogenetic response in myelodysplastic syndromes.
What this means for the patient
Alan F. List Malignant Hematology Division, Department of
Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute,
University of South Florida College of Medicine, Tampa, FL, USA
Myelodysplastic syndromes (MDS) constitute a spectrum of haeÂmatopoietic stem cell malignancies characterized by ineffective haematopoiesis, peripheral cytopenia, and increased risk of acute myeloid leukaemia (AML). Refractory anaemia is the presenting feature in approximately two-thirds of patients, with anaemia usually developing in the remainder as the disease progresses.
[>Read full article in PDF]